XORTX Therapeutics Inc. Common Shares (XRTX)

About XRTX

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injur…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

www.xortx.com/

Fundamentals

1-day range

$2.3$2.44

Market cap

$3.69M

P/E (trailing)

—

P/E (forward)

2.92

EPS (trailing)

$-2.65

Dividend yield

—

Beta

0.03

Avg. volume

13.6K

XORTX Therapeutics Inc. Common Shares Competitors

Chosen by industry and closest market cap.

• XRTX

  XORTX Therapeutics Inc. Common Shares

  $2.34

  ▼ 4.18%
  Market cap $3.69MP/E —
  $2.42$9.85
• PPCB

  Propanc Biopharma Inc. Common Stock

  $1.4

  ▼ 37.22%
  Market cap $3.68MP/E —
  $0.95$85.5
• MBIO

  Mustang Bio Inc. Common Stock

  $0.5375

  ▼ 2.27%
  Market cap $3.88MP/E —
  $0.525$1.85
• RDHL

  Redhill Biopharma Ltd. American Depositary Shares

  $0.6899

  ▲ 9.51%
  Market cap $3.95MP/E —
  $0.57$2.79
• REVB

  Revelation Biosciences Inc. Common Stock

  $1.05

  ▲ 1.94%
  Market cap $3.99MP/E 0.04
  $0.875$11.6
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $4.02MP/E —
  $3.18$71.5
• INM

  InMed Pharmaceuticals Inc. Common Shares

  $1.43

  ▼ 0.35%
  Market cap $4.09MP/E —
  $0.575$2.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency
  benzinga · 8/28/2026

Institutional Ownership

March 31, 2026

Total shares held

15.3K

Total value held

$6.2K

Institutional holders

2